Medical device giants Edwards Lifesciences Corp. and Boston Scientific Corp. have obtained new CE marks on their transcatheter aortic valve replacement (TAVR) products, the companies announced at the ongoing Paris Course of Revascularization (PCR) London Valves meeting in London.
Edwards’ Sapien 3 valve has been granted a CE mark to use the device in patients suffering from severe, symptomatic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?